Watanabe, Kenji
Tanida, Satoshi
Inoue, Nagamu
Kunisaki, Reiko
Kobayashi, Kiyonori
Nagahori, Masakazu
Arai, Katsuhiro
Uchino, Motoi
Koganei, Kazutaka
Kobayashi, Taku
Takeno, Mitsuhiro
Ueno, Fumiaki
Matsumoto, Takayuki
Mizuki, Nobuhisa
Suzuki, Yasuo
Hisamatsu, Tadakazu
Article History
Received: 25 February 2020
Accepted: 8 April 2020
First Online: 7 May 2020
Conflict of interest
: The authors have the following financial conflicts of interest regarding this manuscript. KW: advisory role for Takeda Pharmaceutical Corporation (TPC), commercial research funding from EA Pharma Corporation (EPC), Abbvie GK (AGK), Mitsubishi Tanabe Pharma (MTP), Kyorin Pharmaceutical Corporation (KPC) and JIMRO Corporation (JC), honoraria from EPC, AGK, MTP, KPC, JC, Mochida Pharmaceutical Corporation (MPC), Janssen Pharmaceutical (JP), TPC and Zeria Pharmaceutical Corporation (ZPO); ST: commercial research funding from EPC and AGK; AK: honoraria from MTP; TK: advisory role for AGK, Eli Lilly, JP, TPC and Robarts Clinical Trials, commercial research funding from EPC, Thermo Fisher Scientific, Alfresa Pharma (AP), Nippon Kayaku Co. Ltd. (NK) and Asahi Kasei Medical (AKM), honoraria from AGK, AP, EPC, JP, JC, NK, MPC, Pfizer Japan Inc. (PJI), TPC, MTP and ZPO; YS: commercial research funding from AGK, MTP, JC, MPC, Kissei Pharmaceutical Corporation and NK. honoraria from AGK, MTP, ZPO, MPC, KPC, JP and EPC; TH: commercial research funding from EPC, MTP, AGK, Daiichi-Sankyo Co. Ltd., TPC, PJI, MPC, NK, KPC, JC, Astellas Pharma Inc., AKM, ZPO and Otsuka Pharmaceutical Co. Ltd, honoraria from EPC, AGK, Celgene K.K., JP, PJI, TPC, MTP, KPC, JC, MPC and Nichi-lko Pharmaceutical Co., Ltd.